Active and Passive Immunization

Fundamental Classification of Immunity

Immunity is defined as the protection developed within an organism against pathogens and their harmful effects. This protection is fundamentally categorized into two types: active immunity and passive immunity. Active immunity refers to individual protection developed after the immune system actively engages with an antigen to make its own antibodies. This can occur through a natural infection or through artificial means such as vaccination. Passive immunity, conversely, is the protection acquired by receiving pre-formed antibodies from another organism, rather than producing them internally. Like active immunity, passive immunity is divided into natural and artificial forms. Natural passive immunity involves the transmission of antibodies from a mother to her baby, while artificial passive immunity involves the transfusion or injection of antibodies into an individual.

Passive immunity possesses distinct characteristics that differentiate it from active immunity. It provides protection without requiring previous exposure to a disease agent, either through prior infection or vaccination. Its effects are immediate upon transfer; however, this protection is generally short-lived, typically lasting only a few months. The lack of duration is attributed to the fact that the supply of antibodies is not replenished by the recipient's own immune system, and no immunological memory is established. Consequently, once the externally sourced antibodies are degraded or cleared from the system, the immunity fades.

Mechanisms and Types of Passive Immunity

Natural passive immunity occurs primarily through two maternal pathways. The first is the transfer of maternal antibodies via the placenta. During pregnancy, IgGIgG antibodies, which are the only class capable of crossing the placenta, travel from the mother's blood circulation into the fetal circulation. This process protects the infant for the first few months of life against specific diseases the mother has immunity to, such as measles and rubella. The structural mechanism for this involves epithelial cells of the placenta that possess a surface receptor called FcRnFcRn. This receptor binds to the FcFc region of the IgGIgG from the mother's bloodstream. The resulting receptor-IgGIgG complex is ingested via endocytosis and transported in a vesicle to the surface membrane in contact with the fetal blood circulation. Following the fusion of the vesicle with the outer membrane, the IgGIgG is released into the fetal circulation, conferring protection.

The second pathway for natural passive immunity is through breast milk, specifically colostrum. Secretory Immunoglobulin A (SIgASIgA) is the dominant immunoglobulin found in human milk. It is synthesized and stored in breast tissue and secreted into the milk. When a baby consumes breast milk, the SIgASIgA effectively 'paints' the intestinal epithelium, protecting mucosal surfaces against the entry of pathogenic bacteria and enteroviruses. It specifically affords protection against organisms such as E. coliE.\text{ coli}, salmonellae, shigellae, streptococci, staphylococci, pneumococci, poliovirus, and rotaviruses. Recent research by Nunes et al. (20172017), Pace et al. (20212021), and Perl et al. (20212021) has also identified influenza-specific and SARS-CoV-2SARS\text{-}CoV\text{-}2-specific IgAIgA in the milk of immunized or recovered mothers. While SIgASIgA is known to regulate the composition and function of the gut microbiota, the exact mechanism for this regulation is still being studied.

Artificial passive immunity involves clinical interventions where immediate protection is required. Antibody injections, or Immunoglobulin Therapy, are utilized after potential exposure to high-risk agents such as hepatitis BB, rabies, or tetanus. Another form is Monoclonal Antibody Treatment, which uses lab-made antibodies like Palivizumab, given to high-risk infants to prevent Respiratory Syncytial Virus (RSVRSV). Finally, antivenom for snake bites is a critical application of artificial passive immunity; it contains antibodies derived from animals, such as horses, that have been immunized with snake venom.

The Nature of Active Immunity and Immunological Memory

Active immunity is the protection developed after exposure to a whole pathogen or its components. Encountering a pathogen triggers both the innate and adaptive immune systems. The activation of the adaptive system leads to the production of pathogen-specific TT cells and BB cells. Cytotoxic TT cells (CD8+CD8^+) are responsible for directly killing infected cells, while Helper TT cells (CD4+CD4^+) stimulate BB cells to differentiate into plasma cells, which then produce antibodies. A crucial outcome of active immunity is the formation of memory TT and BB cells. These cells can persist for years, enabling a significantly faster and stronger immune response upon future exposure to the same pathogen.

The process of active immunization (vaccination) mimics this natural process by using microbes or microbial components to activate the individual's immune system. Unlike passive immunization, which acts immediately but temporarily, active immunization has a delay in the onset of protective antibodies but provides long-term protection through immunological memory. The interaction between innate and adaptive immunity involves inflammation and the release of cytokines, which recruit macrophages, neutrophils, and dendritic cells. In TT-cell independent activation, pathogens can trigger short-lived plasma BB cells to produce antibodies through BCR engagement and subsequent clonal expansion.

Vaccine Mechanism and Memory Cell Formation Kinetics

The mechanism of vaccine-induced immunity begins at the site of administration, typically the skin or muscle. The vaccine contains an antigen and often an adjuvant, which provides 'danger signals' to stimulate immune cells. Dendritic cells use Pattern Recognition Receptors (PRRPRR) to detect these signals, then undergo activation and trafficking to the draining lymph node. In the lymph node, antigens are presented via MHCMHC class IIII to CD4+CD4^+ TT cells. With TT cell help, BB cells proliferate and differentiate into memory BB cells or plasma cells. Some plasma cells become long-lived and migrate to the bone marrow. Antigens can also be presented via MHCMHC class II to CD8+CD8^+ TT cells, creating effector and memory CD8+CD8^+ TT cells.

The kinetics of the antibody response are captured through primary and secondary immune responses. Upon the initial exposure to an antigen (AA), there is a primary immune response characterized by a relative delay and lower antibody titers. Upon a secondary exposure to the same antigen, memory BB cells rapidly differentiate into plasma cells, resulting in a much higher and faster antibody response. The effectiveness of this response depends on the incubation period of the pathogen. For pathogens with long incubation periods, such as the Hepatitis BB virus, the secondary immune response has sufficient time to raise antibody levels above the protective threshold. However, for pathogens with short incubation periods, such as Haemophilus influenzaeHaemophilus\text{ influenzae} type bb, there may be insufficient time to raise protective levels despite the presence of memory cells. Some vaccines, such as those for yellow fever, provide lifelong protective antibody levels after the primary series.

Antibody Structure and Immunoglobulin Types

Antibodies, or Immunoglobulins (IgIg), are YY-shaped proteins consisting of two arms. The variable regions at the ends of these arms form antigen-binding sites, which are specific to a particular antigen. The binding follows a lock-and-key mechanism where the antigen combines with the antibody at a specific site called an epitope. The epitope is the part of the antigen recognized by the host's immune system. Structurally, antibodies can exist as single YY-shaped monomers, paired dimers, or clusters of five molecules known as pentamers. Their functions include neutralization, where they coat viruses and toxins to remove their threat, and the formation of immune complexes, which are clumps of antigens and antibodies that are subsequently removed by the body.

There are five primary types of immunoglobulins, each with specific locations and roles. IgGIgG is the main antibody for long-term immunity, found in blood, extracellular fluid, and the placenta; it neutralizes toxins, activates the complement system, and is the only antibody to provide natural passive immunity to a fetus. IgAIgA is found in mucus, saliva, tears, and breast milk, providing mucosal immunity and passive immunity to infants. IgMIgM is the first antibody produced in a primary response and is a strong complement activator found in blood and lymphatic fluid. IgEIgE is bound to mast cells and basophils, playing a central role in allergic reactions and protection against parasitic infections. IgDIgD, located on the surface of immature BB cells, is thought to help initiate BB cell activation, though its full role is not yet understood.

The Requirements and History of Vaccination

A suitable vaccine must meet several rigorous requirements. It must be effective, evoking protective levels of immunity (AbAb, TcTc, TH1TH1, TH2TH2) at the appropriate site for an adequate duration. It must be available, meaning it can be cultured in bulk or accessed via subunit technology. Stability is essential, as the vaccine should remain stable under extreme climates, preferably without the need for refrigeration. It must be economical to remain accessible to developing countries, often with the help of the World Health Organization (WHOWHO). Finally, safety is paramount; all pathogenicity must be eliminated. Vaccines typically consist of one or more antigens, preservatives, emulsifiers, or stabilizers. Non-live vaccines often feature an adjuvant, such as aluminum hydroxide, which improves the immune response by prolonging antigen presence at the injection site and stimulating cytokines.

Modern immunization was established in 17961796 by Edward Jenner. Jenner observed that milkmaids who contracted cowpox—a mild disease characterized by pustules and aches—did not contract smallpox, a deadly disease causing disfigurement and blindness. He inoculated a boy with cowpox pus and later "challenged" him with smallpox material. The boy did not develop smallpox due to cross-protection. This discovery paved the way for the dramatic reduction in deadly infectious diseases globally.

Specialized Vaccine Technologies and Modern Classifications

Vaccines are classified by their technological approach. Live attenuated vaccines, such as those for measles, mumps, rubella (MMRMMR), yellow fever, and BCGBCG, use a weakened form of the pathogen that replicates to mimic natural infection without causing disease. Killed or inactivated vaccines, such as the Inactivated Polio Vaccine (IPVIPV) and Hepatitis AA, use non-replicating pathogens to stimulate an immune response without risk of infection. Subunit or conjugate vaccines, used for Hepatitis BB and HPVHPV, contain only specific protein or sugar parts of the pathogen. Toxoid vaccines, such as those for tetanus and diphtheria, use formaldehyde-inactivated toxins to induce immunity against the toxin rather than the bacteria itself.

Modern advancements have introduced nucleic acid and viral vector technologies. mRNA vaccines, like the Pfizer and Moderna COVID-19COVID\text{-}19 vaccines, do not contain viral material but provide genetic instructions for host cells to produce a specific viral protein (e.g., the SS protein), triggering adaptive immunity. Viral vector vaccines, used for Ebola or some COVID-19COVID\text{-}19 versions (AstraZeneca, J\text{&}J), use a harmless, modified version of a different virus to deliver genes that instruct cells to make the target antigen. Protein subunit vaccines for COVID-19COVID\text{-}19 include only the harmless SS proteins to stimulate the immune system. Other listed technologies include virus-like particles and outer membrane vesicles, used in vaccines like the Group BB meningococcal vaccine.

National Childhood Immunisation Schedule - Singapore

In Singapore, the National Childhood Immunisation Schedule covers individuals from birth up to <18< 18 years of age. At birth, infants receive the BCGBCG (Bacillus Calmette-GuerinBacillus\text{ Calmette-Guerin}) and the first dose of Hepatitis BB (HepBHepB). The second HepBHepB dose follows at 11 month. At 33, 44, and 55 months, the schedule includes (D1)(D1), (D2)(D2), and (D3)(D3) of DTaPDTaP (Paediatric diphtheria and tetanus toxoids and acellular pertussis), IPVIPV (Inactivated polio vaccine), and HibHib (Haemophilus influenzaeHaemophilus\text{ influenzae} type bb). The third HepBHepB dose (D3D3) is usually given at 66 months, often coinciding with the other series for convenience.

At 1212 months, the first dose of MMRMMR (Measles, mumps, and rubella) and the first dose of PCVPCV (Pneumococcal conjugate vaccine) are administered. Between 1515 and 1818 months, children receive boosters for DTaPDTaP, IPVIPV, and HibHib (B1B1), the second dose of PCVPCV (D2D2), and the second dose of MMRMMR. A subsequent PCVPCV booster (B1B1) is given at 1818 months. Later vaccinations include a TdapTdap (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) and IPVIPV booster at Primary 11 (6-76\text{-}7 years), and OPVOPV (Oral polio vaccine) or further boosters at Primary 55 (10-1110\text{-}11 years). Human Papillomavirus (HPVHPV) vaccination is recommended for females aged 99 to 2626 years in three doses at intervals of 00, 22, and 66 months.

Summary of Vaccination Impact and Challenges

The primary advantages of vaccines include the prevention of infectious diseases, the development of herd immunity which protects the unvaccinated, and a reduction in long-term healthcare costs. Vaccines induce immune memory and are rigorously tested for safety. However, challenges persist, including potential mild side effects like fever or soreness, the requirement for high coverage to maintain herd immunity, and the initial costs of development and distribution. Furthermore, public health efforts must contend with misinformation and vaccine hesitancy, as well as the need for booster shots for certain pathogens to maintain protection over time.